13847/34347US=9 / Urologia
Schally AV, Block NL. Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 27-39. ISBN 978-1-60327-831-7.

CANCER DE PROSTATA; SECRECAO DE LH; SECRECAO FSH; ESTEROIDES SEXUAIS; GONADOTROFINA; CASTRACAO QUIMICA; EFEITOS ANTICANCERIGENOS; CRESCIMENTO DO TUMOR; PROLIFERACAO CELULAR; RECEPTOR LHRH

13848/34347US=109 / Câncer
Wieczorek T, Longtine JA. The role of molecular probes and other markers in the diagnosis of malignancy. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 1-5. ISBN 978-0-323-05905-3.

CANCER; SONDAS MOLECULARES; MARCADORES

13849/34347US=9 / Urologia
Heemers HV, Tindall DJ. Nuclear receptor coregulators: promising therapeutic targets for the treatment of prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 41-51. ISBN 978-1-60327-831-7.

CANCER DE PROSTATA. TRATAMENTO; RECEPTOR DE ANDROGENO; ANDROGENO; COATIVADOR; COREPRESSOR; PROLIFERACAO CELULAR

13850/34347US=9 / Urologia
Prince DK, Hsing AW. Androgens and prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 53-9. ISBN 978-1-60327-831-7.

CANCER DE PROSTATA; ANDROGENOS; TESTOSTERONA; TERAPIA DE REPOSICAO

13851/34347US=109 / Câncer
Shaffer K. Radiographic evaluation of cancer. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 6-29. ISBN 978-0-323-05905-3.

CANCER; AVALIACAO RADIOGRAFICA; IMAGEM; RADIOGRAFIA SIMPLES; EXAMES CONTRASTADOS; MAMOGRAFIA; ULTRA-SOM; TOMOGRAFIA COMPUTADORIZADA; TOMOGRAFIA POR EMISSAO DE POSITRONS; RESSONANCIA MAGNETICA (MRI); BIOPSIA GUIADA POR IMAGEM; TERAPIA GUIADA POR IMAGEM

13852/34347US=9 / Urologia
Gelmann EP. Androgen receptor biology in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 61-70. ISBN 978-1-60327-831-7.

ANDROGENO RECEPTOR DE BIOLOGIA; CANCER DE PROSTATA; RECEPTOR DE ANDROGENO; ANDROGENO; MUTACAO; COATIVADOR; BETA-CATENINA; P160

13853/34347US=109 / Câncer
Burrell S, Van Den Abbeele AD. Nuclear medicine in oncology. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 30-59. ISBN 978-0-323-05905-3.

CANCER; MEDICINA NUCLEAR; CINTILOGRAFIA OSSEA; TOMOGRAFIA POR EMISSAO DE POSITRONS; CANCER DE TIREOIDE; TUMORES NEUROENDOCRINOS; LINFONODO SENTINELA; RADIOISOTOPOS

13854/34347US=9 / Urologia
Shen HC, Taplin ME, Balk SP. Androgen receptor antagonists. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 71-81. ISBN 978-1-60327-831-7.

ANTAGONISTAS DO RECEPTOR DE ANDROGENO; CANCER PROSTATA; ESTEROIDES; ESTEROIDE RECEPTOR; TESTOTERONA; DIIDROTESTOSTERONA; ANTAGONISTA; BICALUTAMIDA; FLUTAMIDA; NILUTAMIDA

13855/34347US=109 / Câncer
Haddad R, Clark JR, Suojanen JN, Colevas AD, Posner M. Cancer of the head and neck region. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 60-97. ISBN 978-0-323-05905-3.

CANCER DE CABECA E PESCOCO; CANCER DE CABECA E PESCOCO. HISTOLOGIA; TUMORES DE GLANDULAS SALIVARES; CANCER DE CABECA E PESCOCO. BIOLOGIA MOLECULAR; CANCER DE CABECA E PESCOCO. ESTADIAMENTO; CANCER DE CABECA E PESCOCO. MANIFESTACOES CLINICAS

13856/34347US=109 / Câncer
Salgia R, Blanco R, Skarin AT. Lung cancer and tumors of the heart and mediastinum. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 98-159. ISBN 978-0-323-05905-3.

CANCER DE PULMAO; TUMORES DO CORACAO; TUMORES DO MEDIASTINO

13857/34347US=9 / Urologia
Culig Z. 5-Alpha reductase inhibitors in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 83-9. ISBN 978-1-60327-831-7.

CANCER DE PROSTATA; 5-ALFA REDUTASE; DUTASTERIDE; FINASTERIDE; ISOENZIMA

13858/34347US=109 / Câncer
Janne PA, Wu D, Chirieac LR. Malignant mesothelioma. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 160-8. ISBN 978-0-323-05905-3.

MESOTELIOMA MALIGNO; MESOTELIOMA. APRESENTACAO CLINICA; MESOTELIOMA. DIAGNOSTICO; MESOTELIOMA. ESTADIAMENTO; MESOTELIOMA. FATORES PROGNOSTICOS; MESOTELIOMA. TRATAMENTO; CIRURGIA; QUIMIOTERAPIA; IRRADIACAO

13859/34347US=109 / Câncer
Meyerhardt JA, Kulke MH, Turner JR. Cancer of the gastrointestinal tract and neuroendocrine tumors. In: Skarin AT. Dana-Faber Cancer Institute: atlas of diagnostic oncology. 4ª ed. Philadelphia: Elsevier Mosby, 2010. p. 169-232. ISBN 978-0-323-05905-3.

CANCER DO TRATO GASTROINTESTINAL; TUMORES NEUROENDOCRINOS; CANCER ESOFAGICO; CANCER GASTRICO; CANCER PANCREATICO; CANCER HEPATOBILIAR; CANCER DE INTESTINO DELGADO; CANCER COLORRETAL; CANCER ANAL

13860/34347US=9 / Urologia
Friedlander TW, Ryan CJ. Adrenal androgen synthesis inhibitor therapies in castration-resistant prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 91-100. ISBN 978-1-60327-831-7.

SINTESE DE ANDROGENOS ADRENAIS; TERAPIAS INIBIDOR NA CASTRACAO-RESISTENTE; CANCER DE PROSTATA; TERAPIA HORMONAL SECUNDARIA; ANDROGENIOS ADRENAIS; ANDROGENO-INDEPENDENTES CANCER DE PROSTATA; CANCER DE PROSTATA HORMONIO REFRATARIO; FASE I; FASE I DE ENSAIOS CLINICOS; FARMACOCINETICA

13861/34347US=9 / Urologia
Sharifi N. Androgen deprivation therapy. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 101-7. ISBN 978-1-60327-831-7.

TERAPIA DE PRIVACAO DE ANDROGENO; TERAPIA DE PRIVACAO DE ANDROGENO; ANDROGENOS; CANCER DE PROSTATA; TESTOSTERONA

13862/34347US=9 / Urologia
Marques FZC, Reichardt JKV. Pharmacogenetics of the androgen metabolic pathway. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 109-21. ISBN 978-1-60327-831-7.

FARMACOGENETICA; ANDROGENOS; DOENCA MULTIFATORIAL; CANCER DE PROSTATA; CANCER DE PROSTATA. TRATRAMENTO; CANCER DE PROSTATA. PREVENCAO; CANCER DE PROSTATA. FARMACOGENETICA

13863/34347US=9 / Urologia
Halterman P, Vogelzang NJ, Farabishahadel A, Goodman Jr OB. Mitoxantrone. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 125-31. ISBN 978-1-60327-831-7.

MITOXANTRONA; DHAD; CANCER DE PROSTATA; CRPC; TERAPIA DE RESGATE

13864/34347US=9 / Urologia
Phillips CK, Petrylak DP. Docetaxel. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 133-46. ISBN 978-1-60327-831-7.

DOCETAXEL; QUIMIOTERAPIA; SOBREVIVENCIA; RESISTENTE A CASTRACAO CANCER DE PROSTATA

13865/34347US=9 / Urologia
Rosenberg J. Beyond Docetaxel: emerging agents in the treatment of advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 147-51. ISBN 978-1-60327-831-7.

DOCETAXEL; CANCER DE PROSTATA AVANCADO; INIBICAO DE MTOR; NOVAS TERAPEUTICAS; DESACETILACAO DAS HISTONAS; HSP90; FATOR 1 DE CRESCIMENTO COM INSULINA

13866/34347US=9 / Urologia
Brick A, Niu J, Huang J, Oh WK. Platinum agents in prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 153-61. ISBN 978-1-60327-831-7.

AGENTES DE PLATINA NO CANCER DE PROSTATA; CARBOPLATINA; NEUROENDOCRINO; RESISTENTE A CASTRACAO; QUIMIOTERAPIA

Primeira | Anterior | Próxima | Última